OncoTherapy Science, Inc.
4564.T
Price:
$20
Market Cap:
$6.77B
OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as...[Read more]
Industry
Biotechnology
IPO Date
2005-09-29
Stock Exchange
JPX
Ticker
4564.T
PE Ratio
[-7.07]
ROE
[-77.04%]
Current Ratio
[8.63]
Dividend Yield
[0%]
Enterprise Value
[5.12B]
Dividend History
The ROE as of December 2025 (TTM) for OncoTherapy Science, Inc. (4564.T) is -77.04%
According to OncoTherapy Science, Inc.’s latest financial reports and current stock price. The company's current ROE is -77.04%. This represents a change of 295.46% compared to the average of -19.48% of the last 4 quarters.
OncoTherapy Science, Inc. (4564.T) Historical ROE (quarterly & annually)
How has 4564.T ROE performed in the past?
The mean historical ROE of OncoTherapy Science, Inc. over the last ten years is -98.50%. The current -77.04% ROE has changed -21.78% with respect to the historical average. Over the past ten years (40 quarters), 4564.T's ROE was at its highest in in the March 2016 quarter at -5.07%. The ROE was at its lowest in in the March 2024 quarter at -85.05%.
Average
-98.50%
Median
-55.51%
Minimum
-364.22%
Maximum
-21.26%
OncoTherapy Science, Inc. (4564.T) ROE by Quarter and Year
Discovering the peaks and valleys of OncoTherapy Science, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 178.44%
Maximum Annual ROE = -21.26%
Minimum Annual Increase = -69.30%
Minimum Annual ROE = -364.22%
| Year | ROE | Change |
|---|---|---|
| 2025 | -111.82% | -69.30% |
| 2024 | -364.22% | 178.44% |
| 2023 | -130.81% | 0.73% |
| 2022 | -129.86% | 155.86% |
| 2021 | -50.75% | 7.21% |
| 2020 | -47.34% | -21.44% |
| 2019 | -60.26% | 54.78% |
| 2018 | -38.93% | 31.04% |
| 2017 | -29.71% | 39.72% |
| 2016 | -21.26% | 155.89% |
OncoTherapy Science, Inc. (4564.T) Average ROE
How has 4564.T ROE performed in the past?
The current ROE of OncoTherapy Science, Inc. (4564.T) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-202.28%
5-year avg
-157.49%
10-year avg
-98.50%
OncoTherapy Science, Inc. (4564.T) ROE vs. Peers
How is 4564.T’s ROE compared to its peers?
OncoTherapy Science, Inc.’s ROE is greater than K Pharma,Inc. (-46.92%), greater than BrightPath Biotherapeutics Co., Ltd. (-92.78%), greater than ADR120S, Inc. (-214.73%), greater than Noile-Immune Biotech Inc. (-17.72%), greater than TMS Co., Ltd. (-22.94%), greater than Linical Co., Ltd. (-17.16%), greater than Chiome Bioscience Inc. (-56.15%), greater than MedRx Co., Ltd (-63.42%), less than Kohjin Bio Co., Ltd. (12.63%), greater than Delta-Fly Pharma, Inc. (-332.90%),
| Company | ROE | Market cap |
|---|---|---|
| -46.92% | $7.45B | |
| -92.78% | $4.35B | |
| -214.73% | $7.42B | |
| -17.72% | $6.15B | |
| -22.94% | $5.91B | |
| -17.16% | $6.64B | |
| -56.15% | $7.28B | |
| -63.42% | $6.24B | |
| 12.63% | $7.72B | |
| -332.90% | $5.75B |
Build a custom stock screener for OncoTherapy Science, Inc. (4564.T) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like OncoTherapy Science, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
OncoTherapy Science, Inc. (4564.T) and other stocks custom spreadsheet templates
The easiest way to analyze a company like OncoTherapy Science, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is OncoTherapy Science, Inc.'s ROE?
How is the ROE calculated for OncoTherapy Science, Inc. (4564.T)?
What is the highest ROE for OncoTherapy Science, Inc. (4564.T)?
What is the 3-year average ROE for OncoTherapy Science, Inc. (4564.T)?
What is the 5-year average ROE for OncoTherapy Science, Inc. (4564.T)?
How does the current ROE for OncoTherapy Science, Inc. (4564.T) compare to its historical average?